Akums Drugs & Pharmaceuticals IPO
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 30 Jul 24 – 1 Aug 24 | ₹14,212 | 22 | ₹646 – ₹679 |
Issue Size | IPO Doc |
|---|---|
| 1856.74Cr | RHP PDF |
About Akums Drugs and Pharmaceuticals Limited
| Founded in | 2004 |
| Managing director | Mr. Sanjeev Jain |
| Parent organisation | Akums Drugs & Pharmaceuticals Ltd |
Akums Drugs and Pharmaceuticals is a company that helps develop and manufacture medicines. They offer services like research, regulatory paperwork, and various tests for their clients in India and around the world.
Besides helping other companies, Akums also sells its own branded medicines in India and internationally through its subsidiaries, Akumentis and Unosource. Akumentis focuses on areas like women’s health, heart conditions, bone health, and children’s health. Unosource specializes in anti-infectives, pain relief, brain-related conditions, and women’s health. Akums operates in 65 countries and works with international clients such as Allegens in Vietnam, Ambica International in the Philippines, and Olainfarm in Latvia.
Open Your Free Demat Account
By Popular Stock Brokers
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
Founded in 2004, Akums has a wide range of products, including tablets, capsules, liquid medicines, and even gummy bears. They have created over 4,000 different formulations and work with many of the top pharmaceutical companies in India. Akums operates 10 manufacturing units with the ability to produce billions of units each year and plans to add two more units by 2025.
As of September 2023, Akums employs over 16,000 people. Some of their facilities are approved by global regulatory bodies like the European GMP, WHO-GMP, and US NSF.
Also Read: 10 Smart Financial Tips to Increase Your Savings
Akums is launching an IPO to raise Rs 1,856.74 crores. This includes a fresh issue of 1 crore shares worth Rs 680.00 crores and an offer for sale of 1.73 crore shares worth Rs 1,176.74 crores. The IPO opens on July 30, 2024, and closes on August 1, 2024. The shares are expected to be listed on the BSE and NSE on August 6, 2024.
The IPO price range is set between ₹646 and ₹679 per share. The minimum investment for retail investors is ₹14,938 for 22 shares. For larger investors, the minimum is ₹209,132 for 308 shares, and ₹1,000,846 for 1,474 shares.
There is also a special reservation of up to 243,902 shares for employees at a discounted price.
ICICI Securities, Axis Bank, Citigroup Global Markets, and Ambit are managing the IPO, with Link Intime India as the registrar.
For more detailed information, refer to the Akums Drugs and Pharmaceuticals IPO RHP (Red Herring Prospectus).
Open Your Free Demat Account
By Popular Stock Brokers
FREE Account Opening & Flat ₹20 Per Trade in F&O
Use code PRA6RI69IND
Financial Information
Akums Drugs and Pharmaceuticals Limited saw its revenue increased by 13.81%, but its profit after tax (PAT) plummeted by 99.19% between the financial years ending March 31, 2023, and March 31, 2024.
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 3,516.37 | 3,266.53 | 3,069.05 |
| Revenue | 4,212.21 | 3,700.93 | 3,694.52 |
| Profit After Tax | 0.79 | 97.82 | -250.87 |
| Net Worth | 709.50 | 717.19 | 621.98 |
| Reserves and Surplus | 861.01 | 868.70 | 787.79 |
| Total Borrowing | 491.56 | 536.97 | 357.95 |
| Amount in ₹ Crore | |||
Open Your Free Demat Account
By Popular Stock Brokers
FREE Account Opening &
Flat ₹20 Per Trade in F&O
IPO Timeline
Akums Drugs and Pharmaceuticals IPO opens on July 30, 2024, and closes on August 1, 2024.
| IPO Open Date | Tuesday, July 30, 2024 |
| IPO Close Date | Thursday, August 1, 2024 |
| Basis of Allotment | Friday, August 2, 2024 |
| Initiation of Refunds | Monday, August 5, 2024 |
| Credit of Shares to Demat | Monday, August 5, 2024 |
| Listing Date | Tuesday, August 6, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on August 1, 2024 |
Open Your Free Demat Account
By Popular Stock Brokers
FREE Account Opening & Flat ₹20 Per Trade in F&O
IPO FAQs
Akums Drugs & Pharmaceuticals is a contract development and manufacturing organization (CDMO) that provides comprehensive solutions for product development, manufacturing, research, and regulatory compliance in the pharmaceutical industry.
Akums operates 10 manufacturing units with a total production capacity of 49.21 billion units annually. They plan to add two more units by 2025.
Akums has a presence in 65 countries worldwide.
The IPO is a book-built issue of Rs 1,856.74 crores, including a fresh issue of 1 crore shares worth Rs 680.00 crores and an offer for sale of 1.73 crore shares worth Rs 1,176.74 crores.
The IPO opens on July 30, 2024, and closes on August 1, 2024.
The IPO price band is set between ₹646 and ₹679 per share.
The minimum investment for retail investors is ₹14,938 for 22 shares. For larger investors, the minimum is ₹209,132 for 308 shares, and ₹1,000,846 for 1,474 shares.
Yes, there is a reservation of up to 243,902 shares for employees, offered at a discount of Rs 64 to the issue price.
ICICI Securities, Axis Bank, Citigroup Global Markets, and Ambit are the book-running lead managers. Link Intime India is the registrar for the IPO.
